FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085165928> ?p ?o ?g. }

• W2085165928 endingPage "1431" @default.
• W2085165928 startingPage "1425" @default.
• W2085165928 abstract "Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective treatment. In an initial study, riluzole decreased mortality and slowed muscle-strength deterioration in ALS patients. We have carried out a double-blind, placebo-controlled, multicentre study to confirm those findings and to assess drug efficacy at different doses.959 patients with clinically probable or definite ALS of less than 5 years' duration were randomly assigned treatment with placebo or 50 mg, 100 mg, or 200 mg riluzole daily; randomisation was stratified by centre and site of disease onset (bulbar or limb). The primary outcome was survival without a tracheostomy. Secondary outcomes were rates of change in functional measures (muscle strength, functional status, respiratory function, patient's assessments of fasciculation, cramps, stiffness, and tiredness). The primary analysis was the comparison of the 100 mg dose with placebo by intention-to-treat. Drug-effect on survival was assessed before (log-rank test) and after adjustment for known prognostic factors (Cox's model).At the end of the study, after median follow-up of 18 months, 122 (50.4%) placebo-treated patients and 134 (56.8%) of those who received 100 mg/day riluzole were alive without tracheostomy (unadjusted risk 0.79, p = 0.076; adjusted risk 0.65, p = 0.002). In the groups receiving 50 mg and 200 mg riluzole daily, 131 (55.3%) and 141 (57.8%) patients were alive without tracheostomy (relative to placebo 50 mg adjusted risk 0.76, p = 0.04; 200 mg 0.61, p = 0.0004). There was a significant inverse dose response in risk of death. No functional scale discriminated between the treatment groups. The most common adverse reactions were asthenia, dizziness, gastrointestinal disorders, and rises in liver enzyme activities; they were commonest with the 200 mg dose.Overall, efficacy and safety results suggest that the 100 mg dose of riluzole has the best benefit-to-risk ratio. This study confirms that riluzole is well tolerated and lengthens survival of patients with ALS." @default.
• W2085165928 created "2016-06-24" @default.
• W2085165928 creator A5010783348 @default.
• W2085165928 creator A5024180184 @default.
• W2085165928 creator A5029754351 @default.
• W2085165928 creator A5057953137 @default.
• W2085165928 creator A5060581186 @default.
• W2085165928 date "1996-05-01" @default.
• W2085165928 modified "2023-10-10" @default.
• W2085165928 title "Dose-ranging study of riluzole in amyotrophic lateral sclerosis" @default.
• W2085165928 cites W1506357578 @default.
• W2085165928 cites W1506512444 @default.
• W2085165928 cites W1964177214 @default.
• W2085165928 cites W1968016528 @default.
• W2085165928 cites W1968042426 @default.
• W2085165928 cites W1968533747 @default.
• W2085165928 cites W1989533240 @default.
• W2085165928 cites W2015807534 @default.
• W2085165928 cites W2038226090 @default.
• W2085165928 cites W2046478987 @default.
• W2085165928 cites W2064951237 @default.
• W2085165928 cites W2065353775 @default.
• W2085165928 cites W2083067786 @default.
• W2085165928 cites W2115979503 @default.
• W2085165928 cites W2314689571 @default.
• W2085165928 cites W4243155135 @default.
• W2085165928 cites W4244616110 @default.
• W2085165928 doi "https://doi.org/10.1016/s0140-6736(96)91680-3" @default.
• W2085165928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8676624" @default.
• W2085165928 hasPublicationYear "1996" @default.
• W2085165928 type Work @default.
• W2085165928 sameAs 2085165928 @default.
• W2085165928 citedByCount "1123" @default.
• W2085165928 countsByYear W20851659282012 @default.
• W2085165928 countsByYear W20851659282013 @default.
• W2085165928 countsByYear W20851659282014 @default.
• W2085165928 countsByYear W20851659282015 @default.
• W2085165928 countsByYear W20851659282016 @default.
• W2085165928 countsByYear W20851659282017 @default.
• W2085165928 countsByYear W20851659282018 @default.
• W2085165928 countsByYear W20851659282019 @default.
• W2085165928 countsByYear W20851659282020 @default.
• W2085165928 countsByYear W20851659282021 @default.
• W2085165928 countsByYear W20851659282022 @default.
• W2085165928 countsByYear W20851659282023 @default.
• W2085165928 crossrefType "journal-article" @default.
• W2085165928 hasAuthorship W2085165928A5010783348 @default.
• W2085165928 hasAuthorship W2085165928A5024180184 @default.
• W2085165928 hasAuthorship W2085165928A5029754351 @default.
• W2085165928 hasAuthorship W2085165928A5057953137 @default.
• W2085165928 hasAuthorship W2085165928A5060581186 @default.
• W2085165928 hasConcept C126322002 @default.
• W2085165928 hasConcept C141071460 @default.
• W2085165928 hasConcept C142724271 @default.
• W2085165928 hasConcept C203092338 @default.
• W2085165928 hasConcept C204787440 @default.
• W2085165928 hasConcept C27081682 @default.
• W2085165928 hasConcept C2778970341 @default.
• W2085165928 hasConcept C2779134260 @default.
• W2085165928 hasConcept C2779319286 @default.
• W2085165928 hasConcept C2780596555 @default.
• W2085165928 hasConcept C42219234 @default.
• W2085165928 hasConcept C50382708 @default.
• W2085165928 hasConcept C535046627 @default.
• W2085165928 hasConcept C71924100 @default.
• W2085165928 hasConceptScore W2085165928C126322002 @default.
• W2085165928 hasConceptScore W2085165928C141071460 @default.
• W2085165928 hasConceptScore W2085165928C142724271 @default.
• W2085165928 hasConceptScore W2085165928C203092338 @default.
• W2085165928 hasConceptScore W2085165928C204787440 @default.
• W2085165928 hasConceptScore W2085165928C27081682 @default.
• W2085165928 hasConceptScore W2085165928C2778970341 @default.
• W2085165928 hasConceptScore W2085165928C2779134260 @default.
• W2085165928 hasConceptScore W2085165928C2779319286 @default.
• W2085165928 hasConceptScore W2085165928C2780596555 @default.
• W2085165928 hasConceptScore W2085165928C42219234 @default.
• W2085165928 hasConceptScore W2085165928C50382708 @default.
• W2085165928 hasConceptScore W2085165928C535046627 @default.
• W2085165928 hasConceptScore W2085165928C71924100 @default.
• W2085165928 hasIssue "9013" @default.
• W2085165928 hasLocation W20851659281 @default.
• W2085165928 hasLocation W20851659282 @default.
• W2085165928 hasOpenAccess W2085165928 @default.
• W2085165928 hasPrimaryLocation W20851659281 @default.
• W2085165928 hasRelatedWork W1992546355 @default.
• W2085165928 hasRelatedWork W2003009591 @default.
• W2085165928 hasRelatedWork W2020935865 @default.
• W2085165928 hasRelatedWork W2021830011 @default.
• W2085165928 hasRelatedWork W2076153179 @default.
• W2085165928 hasRelatedWork W2085165928 @default.
• W2085165928 hasRelatedWork W2113542630 @default.
• W2085165928 hasRelatedWork W2147955864 @default.
• W2085165928 hasRelatedWork W2314689571 @default.
• W2085165928 hasRelatedWork W3006375948 @default.
• W2085165928 hasVolume "347" @default.
• W2085165928 isParatext "false" @default.
• W2085165928 isRetracted "false" @default.
• W2085165928 magId "2085165928" @default.

• next